Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy
Open accessThe DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Spinal muscular atrophy type 1 (SMA1) is a progressive, monogenic motor neuron disease with an onset during infancy that results in failure to achieve motor milestones and in death or the need for mechanical ventilation by 2 years of age. We studied functional replacement of the mutated gene encoding survival motor neuron 1 (SMN1) in this disease. METHODS: vg per kilogram). The primary outcome was safety. The secondary outcome was the time until death or the need for permanent ventilatory assistance. In exploratory analyses, we compared scores on the CHOP INTEND (Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders) scale of motor function (ranging from 0 to 64, with higher scores indicating better function) in the two cohorts and motor milestones in the high-dose cohort with scores in studies of the natural history of the disease (historical cohorts). RESULTS: As of the data cutoff on August 7, 2017, all 15 patients were alive and event-free at 20 months of age, as compared with a rate of survival of 8% in a historical cohort. In the high-dose cohort, a rapid increase from baseline in the score on the CHOP INTEND scale followed gene delivery, with an increase of 9.8 points at 1 month and 15.4 points at 3 months, as compared with a decline in this score in a historical cohort. Of the 12 patients who had received the high dose, 11 sat unassisted, 9 rolled over, 11 fed orally and could speak, and 2 walked independently. Elevated serum aminotransferase levels occurred in 4 patients and were attenuated by prednisolone. CONCLUSIONS: In patients with SMA1, a single intravenous infusion of adeno-associated viral vector containing DNA coding for SMN resulted in longer survival, superior achievement of motor milestones, and better motor function than in historical cohorts. Further studies are necessary to confirm the safety and efficacy of this gene therapy. (Funded by AveXis and others; ClinicalTrials.gov number, NCT02122952 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Notably, the FDA has approved AAV for gene replacement therapy in spinal muscular atrophy and congenital blindness, and clinical trials are in progress 58 .”
From The promise and challenge of therapeutic genome editing (2020) · cites this paper as [58]
In the citing paper
“preclinical and clinical studies have demonstrated dose-dependent inflammation, which can reduce efficacy and lead to dose-limiting toxicity (2–8)”
From Engineering adeno-associated viral vectors to evade innate immune and inflammatory responses (2021) · cites this paper as [4]
In the citing paper
“Although neuroimaging is typically more expensive than EEG and studies are limited by issues of replication, sometimes that is related to head motion that occurred during the scan which can erode signal 61”
From Autism spectrum disorder (2020) · cites this paper as [61]
In the citing paper
“Especially considering the ability of the recombinant AAV genome to persist as an episome in post-mitotic cells, such as neurons, which ensures long-term expression even after a single administration [130-132].”
From Circumventing the packaging limit of AAV-mediated gene replacement therapy for neurological disorders (2022) · cites this paper as [132]
In the citing paper
“With AAV9’s inherent ability to target motor neurons, AAV9-based Zolgensma® for the treatment of SMA has been established as the first FDA-approved drug for systemic gene therapy in CNS diseases [171].”
From Designing and optimizing AAV-mediated gene therapy for neurodegenerative diseases: from bench to bedside (2024) · cites this paper as [171]
12 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
1 retracted
Foust, K. D., Wang, X., McGovern, V. L., Braun, L., Bevan, A. K., Haidet, A. M., Le, T. T., Morales, P. R., Rich, M. M., Burghes, A. H. M., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1610 · Cited by 688
Self-citationRetractedDeaths: preliminary data for 2003.
Hoyert, D. L., Kung, H.-C., & Smith, B. L. (2005) · PubMed · Cited by 1,649
Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes
Foust, K. D., Nurre, E., Montgomery, C. L., Hernandez, A., Chan, C. M., & Kaspar, B. K. (2009) · Nature Biotechnology · doi:10.1038/nbt.1515 · Cited by 1,456
Self-citationBayley Scales of Infant and Toddler Development, Third Edition
Bayley, N. (2012) · PsycTESTS Dataset · doi:10.1037/t14978-000 · Cited by 1,175
National Vital Statistics Reports NCHS.pdf
Hoyert, D. (2012) · Medical Entomology and Zoology · Cited by 982
Consensus Statement for Standard of Care in Spinal Muscular Atrophy
Wang, C. H., Finkel, R. S., Bertini, E. S., Schroth, M., Simonds, A., Wong, B., Aloysius, A., Morrison, L., Main, M., Crawford, T. O., et al. (2007) · Journal of Child Neurology · doi:10.1177/0883073807305788 · Cited by 961 · cited 4×
“Viral upper respiratory tract infection 0 0 3 3 (25) 3 3 (20)”
InfluentialAntisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model
Hua, Y., Sahashi, K., Hung, G., Rigo, F., Passini, M. A., Bennett, C. F., & Krainer, A. R. (2010) · Genes & Development · doi:10.1101/gad.1941310 · Cited by 664
Sugarman, E. A., Nagan, N., Zhu, H., Akmaev, V. R., Zhou, Z., Rohlfs, E. M., Flynn, K., Hendrickson, B. C., Scholl, T., Sirko-Osadsa, D. A., et al. (2012) · European Journal of Human Genetics · doi:10.1038/ejhg.2011.134 · Cited by 661
Passini, M. A., Bu, J., Richards, A. M., Kinnecom, C., Sardi, S. P., Stanek, L. M., Hua, Y., Rigo, F., Matson, J., Hung, G., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001777 · Cited by 547
de Onis, M., Onyango, A. W., Van den Broeck, J., Chumlea, W. C., & Martorell, R. (2004) · Food and Nutrition Bulletin · doi:10.1177/15648265040251s105 · Cited by 529
Research works printed but not linked: 1
- Hoyert DL, 2012, Natl Vital Stat Rep, 61, 1
Cited by
Items 701–800 of 1,005
Smith-Moore, S., Neil, S. J. D., Fraefel, C., Linden, R. M., Bollen, M., Rowe, H. M., & Henckaerts, E. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1721883115 · Cited by 29
Maxwell, G. K., Szunyogová, E., Shorrock, H. K., Gillingwater, T. H., & Parson, S. H. (2018) · Journal of Anatomy · doi:10.1111/joa.12793 · Cited by 34
Vita, G., Vita, G. L., Musumeci, O., Rodolico, C., & Messina, S. (2019) · Neurological Sciences · doi:10.1007/s10072-019-03764-z · Cited by 31
Ginocchio, V. M., Ferla, R., Auricchio, A., & Brunetti‐Pierri, N. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.151 · Cited by 30
“…trial for spinal muscular atrophy type 1 (SMA), 12 without reported serious treatment-related adverse events besides increased transaminases 12 and based on results from a phase 3 clinical trial (NCT03461289), the Food and Drug Administration has recently approved the AAV-based gene…”
Garlid, A. O., Schaffer, C. T., Kim, J., Bhatt, H., Guevara-Gonzalez, V., & Ping, P. (2019) · Gene · doi:10.1016/j.gene.2019.144148 · Cited by 31
Martin, A., Wolcott, N. S., & O’Connell, L. A. (2020) · Journal of Experimental Biology · doi:10.1242/jeb.208793 · Cited by 28
Yin, L., Keeler, G. D., Zhang, Y., Hoffman, B. E., Ling, C., Qing, K., & Srivastava, A. (2020) · Gene Therapy · doi:10.1038/s41434-020-0140-1 · Cited by 30
“ciency [33], Hemophilia B [34–39], aromatic L-amino acid decarboxylase deficiency [40], choroideremia [41], Leber hereditary optic neuropathy [42], hemophilia A [37], and spinal muscular atrophy [43].”
BackgroundYoon, S. Y., Hunter, J. E., Chawla, S., Clarke, D. L., Molony, C. M., O’Donnell, P. A., Bagel, J. H., Kumar, M., Poptani, H., Vite, C. H., et al. (2020) · Brain · doi:10.1093/brain/awaa161 · Cited by 28
“Gene transduction of cells is concentrated in the lower brain and spinal cord and relatively few cells are transduced in the forebrain (Duque et al., 2009; Bevan et al., 2011; Gray et al., 2011; Samaranch et al., 2012; Yang et al., 2014; Gurda et al., 2016; Mendell et al., 2017).”
BackgroundA comparison of AAV-vector production methods for gene therapy and preclinical assessment
Davidsson, M., Negrini, M., Hauser, S., Svanbergsson, A., Lockowandt, M., Tomasello, G., Manfredsson, F. P., & Heuer, A. (2020) · Scientific Reports · doi:10.1038/s41598-020-78521-w · Cited by 31
Megalencephalic Leukoencephalopathy: Insights Into Pathophysiology and Perspectives for Therapy
Bosch, A., & Estévez, R. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.627887 · Cited by 30
“Encouraging results for spinal muscular atrophy and Mucopolysaccharidosis type IIIA have been reported so far (NCT02122952 and NCT04088734 in www.clinicaltrials.gov, respectively; Mendell et al., 2017).”
BackgroundKofoed, R. H., Heinen, S., Silburt, J., Dubey, S., Dibia, C. L., Maes, M. S., Simpson, E. M., Hynynen, K., & Aubert, I. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.10.001 · Cited by 31
AAV-p40 Bioengineering Platform for Variant Selection Based on Transgene Expression
Westhaus, A., Cabanes‐Creus, M., Jonker, T., Sallard, E., Navarro, R. G., Zhu, E., Torres, G. B., Lee, S. D., Wilmott, P., Gonzalez-Cordero, A., et al. (2022) · Human Gene Therapy · doi:10.1089/hum.2021.278 · Cited by 28
Yang, Y., Seok, M., Kim, Y. E., Choi, Y., Song, J., Sulistio, Y. A., Kim, S., Chang, M., Oh, S., Nam, M., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01693-6 · Cited by 32
“4C) and by western blotting (WB) analysis for A β (cortical homogenates)(Fig.”
Bonanno, S., Cavalcante, P., Salvi, E., Giagnorio, E., Malacarne, C., Cattaneo, M., Andreetta, F., Venerando, A., Pensato, V., Gellera, C., et al. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2022.982760 · Cited by 30
“For this reason, increasing SMN protein production by SMN2 is the target of two out of the three recently approved therapies for the treatment of SMA, being the third directed to reintroduce SMN1 gene (Finkel et al., 2017; Mendell et al., 2017; Darras et al., 2021; Mercuri et al., 2021).”
BackgroundIavarone, M., Monda, E., Vritz, O., Albert, D. C., Rubino, M., Verrillo, F., Caiazza, M., Lioncino, M., Amodio, F., Guarnaccia, N., et al. (2022) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2022.06.003 · Cited by 31
Logan, G. J., Mietzsch, M., Khandekar, N., D’Silva, A., Anderson, D., Mandwie, M., Hsi, J., Nelson, A. R., Chipman, P. R., Jackson, J., et al. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.03.032 · Cited by 31
Commercialization of regenerative-medicine therapies
Takahashi, T., Donahue, R. P., Nordberg, R. C., Hu, J. C. Y., Currall, S. C., & Athanasiou, K. A. (2023) · Nature Reviews Bioengineering · doi:10.1038/s44222-023-00095-9 · Cited by 32
Biswas, M., Marsic, D., Li, N., Zou, C., González‐Aseguinolaza, G., Zolotukhin, I., Kumar, S. R. P., Rana, J., Butterfield, J. S. S., Kondratov, O., et al. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.09.019 · Cited by 30
Shay, T. F., Jang, S., Brittain, T. J., Chen, X., Walker, B., Tebbutt, C., Fan, Y., Wolfe, D. A., Arokiaraj, C. M., Sullivan, E. E., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52149-0 · Cited by 30
An artificial intelligence-driven revolution in orthopedic surgery and sports medicine
Guan, J., Li, Z., Sheng, S., Lin, Q., Wang, S., Wang, D., Chen, X., & Su, J. (2024) · International Journal of Surgery · doi:10.1097/js9.0000000000002187 · Cited by 33
Peeling back the layers of immunogenicity in Cas9-based genomic medicine
Stigzelius, V., Cavallo, A. L., Chandode, R. K., & Nitsch, R. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.06.045 · Cited by 33
To trach or not to trach, that is the question
Macauley, R. C. (2018) · Paediatric Respiratory Reviews · doi:10.1016/j.prrv.2018.05.004 · Cited by 31
Allardyce, H., Kühn, D., Hernandez‐Gerez, E., Hensel, N., Huang, Y.-T., Faller, K. M. E., Gillingwater, T. H., Quondamatteo, F., Claus, P., & Parson, S. H. (2020) · Human Molecular Genetics · doi:10.1093/hmg/ddaa126 · Cited by 27
Nuñez‐Peralta, C., Alonso‐Pérez, J., & Díaz‐Manera, J. (2020) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000851 · Cited by 29
Economic burden of spinal muscular atrophy: an analysis of claims data
Belter, L. T., Cruz, R. E., Kulas, S., McGinnis, E. L., Dabbous, O. H., & Jarecki, J. (2020) · Journal of Market Access & Health Policy · doi:10.1080/20016689.2020.1843277 · Cited by 31
“significantly improve clinical outcomes for patients with SMA [14,16,24].”
BackgroundInfluentialAdeno-associated virus (AAV) capsid engineering in liver-directed gene therapy
Rodríguez-Márquez, E., Meumann, N., & Büning, H. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1865303 · Cited by 30
“on myotubular myopathy (MTM) in which a maximum dose of 3 × 10(14) vg/kg was administered [135], Srivastava hypothesized that vector doses of 2 × 10(12) vg/kgBW, which correlates to 4.”
BackgroundPhenotypes of SMA patients retaining SMN1 with intragenic mutation
Wijaya, Y. O. S., Rohmah, M. A., Niba, E. T. E., Morisada, N., Noguchi, Y., Hidaka, Y., Ozasa, S., Inoue, T., Shimazu, T., Takahashi, Y., et al. (2021) · Brain and Development · doi:10.1016/j.braindev.2021.03.006 · Cited by 28
On the Corner of Models and Cure: Gene Editing in Cystic Fibrosis
Ensinck, M. M., Mottais, A., Detry, C., Leal, T., & Carlon, M. S. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.662110 · Cited by 32
“, 2017), spinal muscular atrophy type 1 (Mendell et al., 2017), and β-thalassemia (Harrison, 2019), have in part revived the interest for CF gene therapy research.”
BackgroundBasic and Preclinical Research for Personalized Medicine
Lattanzi, W., Ripoli, C., Greco, V., Barba, M., Iavarone, F., Minucci, A., Urbani, A., Grassi, C., & Parolini, O. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11050354 · Cited by 32
Synergistic Deoxynucleoside and Gene Therapies for Thymidine Kinase 2 Deficiency
Gomez, C. L., Sanchez‐Quintero, M. J., Lee, E. J., Kleiner, G., Tadesse, S., Xie, J., Akman, H. O., Gao, G., & Hirano, M. (2021) · Annals of Neurology · doi:10.1002/ana.26185 · Cited by 30
Leveraging rAAV bioprocess understanding and next generation bioanalytics development
Escandell, J. M., Pais, D. A. M., Carvalho, S. B., Vincent, K. A., Gomes‐Alves, P., & Alves, P. M. (2022) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2021.12.009 · Cited by 32
Drug treatment for spinal muscular atrophy type I
Wadman, R. I., van der Pol, W. L., Bosboom, W. M., Asselman, F., van den Berg, L. H., Iannaccone, S. T., & Vrancken, A. F. J. E. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006281.pub5 · Cited by 32
Gene-based therapeutics for rare genetic neurodevelopmental psychiatric disorders
Davidson, B. L., Gao, G., Berry‐Kravis, E., Bradbury, A. M., Bönnemann, C. G., Buxbaum, J. D., Corcoran, G. R., Gray, S. J., Gray‐Edwards, H. L., Kleiman, R. J., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.05.014 · Cited by 32
“30 No 7 July 2022 Similar to pre-clinical studies, the timing of delivery was essential, with early treatment of symptomatic infants before 6 months or treatment of asymptomatic infants showing the best neurological outcomes.(83) This AAV9-mediated SMN1 gene therapy (known as Zolgensma or onasemnogene abeparvovec-xioi…”
BackgroundMethodLiver-Directed Adeno-Associated Virus–Mediated Gene Therapy for Mucopolysaccharidosis Type VI
Brunetti‐Pierri, N., Ferla, R., Ginocchio, V. M., Rossi, A., Fecarotta, S., Romanò, R., Parenti, G., Yıldız, Y., Zancan, S., Pecorella, V., et al. (2022) · NEJM Evidence · doi:10.1056/evidoa2200052 · Cited by 30
Beattie, C. E., & Kolb, S. J. (2018) · Brain Research · doi:10.1016/j.brainres.2018.02.022 · Cited by 34
Fitzgerald, D. A., Doumit, M., & Abel, F. (2018) · Paediatric Respiratory Reviews · doi:10.1016/j.prrv.2018.07.002 · Cited by 27
Liver depot gene therapy for Pompe disease
Kishnani, P. S., & Koeberl, D. D. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.05.02 · Cited by 30
7T MRI Predicts Amelioration of Neurodegeneration in the Brain after AAV Gene Therapy
Gray‐Edwards, H. L., Maguire, A. S., Salibi, N., Ellis, L. E., Voss, T. L., Diffie, E. B., Koehler, J. W., Randle, A. N., Taylor, A. R., Brunson, B. L., et al. (2019) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2019.11.023 · Cited by 27
Motor transmission defects with sex differences in a new mouse model of mild spinal muscular atrophy
Deguise, M., Repentigny, Y. D., Tierney, A., Beauvais, A., Michaud, J., Chehadé, L., Thabet, M., Paul, B., Reilly, A., Gagnon, S., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102750 · Cited by 27
“More recently, Zolgensma, the AAV9-SMN based gene therapy, also received FDA approval and is becoming available in the clinic [7].”
BackgroundTrenkle, J., Brugman, J., Peterson, A., Roback, K., & Krosschell, K. J. (2021) · Neuromuscular Disorders · doi:10.1016/j.nmd.2021.02.011 · Cited by 31
Metabolic Transporters in the Peripheral Nerve—What, Where, and Why?
Rawat, A. K., & Morrison, B. M. (2021) · Neurotherapeutics · doi:10.1007/s13311-021-01150-2 · Cited by 28
“The most prominent success has come in the treatment of spinal muscular atrophy [150], but there are also late stage clinical trials for Duchenne’s muscular dystrophy [151], amyotrophic lateral sclerosis [152], and Huntington’s disease [153].”
BackgroundKitzler, T. M., & Chun, J. (2023) · Canadian Journal of Kidney Health and Disease · doi:10.1177/20543581231154185 · Cited by 35
Neurodegenerative Diseases: New Hopes and Perspectives
Bhat, M. A., & Dhaneshwar, S. S. (2023) · Current Molecular Medicine · doi:10.2174/1566524023666230907093451 · Cited by 31
Wouters, F., Bogie, J. F. J., Wullaert, A., & van der Hilst, J. C. H. (2023) · Journal of Clinical Immunology · doi:10.1007/s10875-023-01621-5 · Cited by 28
Taldefgrobep Alfa and the Phase 3 RESILIENT Trial in Spinal Muscular Atrophy
Servais, L., Lair, L. L., Connolly, A. M., Byrne, B. J., Chen, K. S., Coric, V., Qureshi, I., Durham, S., Campbell, D. J., Maclaine, G. D. H., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910273 · Cited by 30
“Onasemnogene abeparvovec is an adeno-associated virus, vector-based gene therapy indicated in patients less than 2 years of age who have SMA and bi-allelic mutations in the SMN1 gene [11,12].”
BackgroundKeyvani, A. H., Mohammadnejad, P., Pazoki–Toroudi, H., Gilabert, I. P., Chu, T., Manshian, B. B., Soenen, S. J., & Sohrabi, B. (2025) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.4c15536 · Cited by 31
In vivo applications and toxicities of AAV-based gene therapies in rare diseases
Zhao, Q., Peng, H., Ma, Y., Yuan, H., & Jiang, H. (2025) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-025-03893-z · Cited by 33
“The results showed that patients had fewer requirements for breath-ventilator treatment and improved motor scores [41].”
Pre-Nusinersen Hospitalization Costs of Children With Spinal Muscular Atrophy
Lee, M. A., França, U. L., Graham, R. J., & McManus, M. L. (2018) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2018.11.002 · Cited by 25
A primer to gene therapy: Progress, prospects, and problems
Zittersteijn, H. A., Gonçalves, M. A. F. V., & Hoeben, R. C. (2020) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12270 · Cited by 30
“Subsequent clinical evaluation in 15 patients demonstrated that a single intravenous infusion of an AAV9 vector encoding SMN1 resulted in longer infant survival and improved motor function compared to historical cohorts.(105) As in the aforementioned hemophilia gene therapy clinical trials, some SMA1 patients required…”
BackgroundResultSystemic Treatment of Fabry Disease Using a Novel AAV9 Vector Expressing α-Galactosidase A
Biferi, M. G., Cohen-Tannoudji, M., García-Silva, A., Souto-Rodríguez, O., Viéitez, I., Millán, B. S., Fernández‐Carrera, A., Pérez-Márquez, T., Teijeira, S., Barrera, S., et al. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.10.016 · Cited by 31
“delivery of scAAV9 vectors has already been approved for gene replacement to treat an infantile form of a rare motor neuron disease.(26,27) For this reason and to facilitate translation into the clinic,”
BackgroundGene Therapy for Inherited Bleeding Disorders
Arruda, V. R., Weber, J., & Samelson‐Jones, B. J. (2021) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0041-1722862 · Cited by 25
Bischof, M., Lorenzi, M. F., Lee, J., Druyts, E., Balijepalli, C., & Dabbous, O. H. (2021) · Current Medical Research and Opinion · doi:10.1080/03007995.2021.1947216 · Cited by 29
Paracha, N., Hudson, P., Mitchell, S., & Sutherland, C. S. (2021) · PharmacoEconomics · doi:10.1007/s40273-021-01105-7 · Cited by 28
“Nusinersen is an intrathecally administered antisense oligonucleotide that modifies SMN2 pre-messenger RNA splicing to increase SMN protein production [26], while onasemnogene abeparvovec is an intravenous gene therapy that introduces a copy of the SMN1 gene [27].”
BackgroundReilly, A., Deguise, M., Beauvais, A., Yaworski, R., Thebault, S., Tessier, D. R., Tabard‐Cossa, V., Hensel, N., Schneider, B. L., & Kothary, R. (2022) · Gene Therapy · doi:10.1038/s41434-022-00338-1 · Cited by 26
“This gene therapy treatment is administered as a one-time intravenous (IV) injection, aiming to induce long-term expression of SMN protein in the periphery as well as the CNS [23, 24].”
MethodHorton, R. H., Saade, D. N., Markati, T., Harriss, E., Bönnemann, C. G., Muntoni, F., & Servais, L. (2022) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2022-329431 · Cited by 32
SMN promotes mitochondrial metabolic maturation during myogenesis by regulating the MYOD-miRNA axis
Ikenaka, A., Kitagawa, Y., Yoshida, M., Lin, C., Niwa, A., Nakahata, T., & Saito, M. K. (2023) · Life Science Alliance · doi:10.26508/lsa.202201457 · Cited by 27
Ishibashi, Y., Sung, C. Y. W., Grati, M., & Chien, W. W. (2023) · Hearing Research · doi:10.1016/j.heares.2023.108735 · Cited by 30
“In addition, the viral titer administered was also reduced to decrease immune activation ( Mendell et al., 2017 ).”
Neuro-Immuno-Gene- and Genome-Editing-Therapy for Alzheimer’s Disease: Are We There Yet?
Raikwar, S. P., Thangavel, R., Dubova, I., Ahmed, M. E., Selvakumar, G. P., Kempuraj, D., Zaheer, S. A., Iyer, S. S., & Zaheer, A. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180422 · Cited by 32
Outcome measures in a cohort of ambulatory adults with spinal muscular atrophy
Elsheikh, B., King, W. M., Peng, J., Swoboda, K. J., Reyna, S. P., LaSalle, B. A., Prior, T. W., Arnold, W. D., Kissel, J. T., & Kolb, S. J. (2019) · Muscle & Nerve · doi:10.1002/mus.26756 · Cited by 27
“More recently, a virally mediated gene therapy approach (Onasemnogene abeparvovec-xioi), was also approved for children under the age of 2 years.(10) Despite these remarkable advances in therapy, there is a lack of consensus on the best outcome measures to use in the adult population with SMA(11-13) and, thus, a press…”
BackgroundSelf-citationDupont, J.-B., Guo, J., Renaud-Gabardos, E., Poulard, K., Latournerie, V., Lawlor, M. W., Grange, R. W., Gray, J. T., Buj‐Bello, A., Childers, M. K., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.10.018 · Cited by 29
Systemic administration of AAV-Slc25a46 mitigates mitochondrial neuropathy in Slc25a46−/− mice
Yang, L., Slone, J. D., Li, Z., Lou, X., Hu, Y., Queme, L. F., Jankowski, M. P., & Huang, T. (2020) · Human Molecular Genetics · doi:10.1093/hmg/ddz277 · Cited by 28
“In contrast to other studies involving gene therapy-based rescue (31,35,36), this dose requirement is relatively high, likely because the Slc25a46 gene is globally expressed in vivo (15).”
ResultAAV9-DOK7 gene therapy reduces disease severity in Smn2B/- SMA model mice
Kaifer, K. A., Villalón, E., Smith, C. E., Simon, M. E., Marquez, J., Hopkins, A. E., Morcos, T. I., & Lorson, C. L. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.07.031 · Cited by 26
Development of new outcome measures for adult SMA type III and IV: a multimodal longitudinal study
Querin, G., Lenglet, T., Debs, R., Stojkovic, T., Béhin, A., Salachas, F., Forestier, N. L., Amador, M. D. M., Bruneteau, G., Laforêt, P., et al. (2021) · Journal of Neurology · doi:10.1007/s00415-020-10332-5 · Cited by 30
Recent Progress in Gene-Targeting Therapies for Spinal Muscular Atrophy: Promises and Challenges
Haque, U. S., & Yokota, T. (2024) · Genes · doi:10.3390/genes15080999 · Cited by 23
“%) compared to the natural history cohort studies, respectively [78,79].”
MethodResultDesguerre, I., Barrois, R., Audic, F., Barnérias, C., Chabrol, B., Davion, J., Durigneux, J., Espil‐Taris, C., de la Banda, M. G. G., Guichard, M., et al. (2024) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-024-03326-3 · Cited by 29
“Onasemnogene abeparvovec is generally well-tolerated, although transitory liver enzyme increases or thrombocytopenia have been documented [8, 13–15].”
BackgroundResultYoussef, E. M., Weddle, K., Zimmerman, L., & Palmer, D. (2025) · Drug Safety · doi:10.1007/s40264-025-01596-9 · Cited by 42
“Onasemno-gene abeparvovec (Zolgensma ® ), which uses an adeno-associated virus 9 (AAV9) to deliver a working SMN1 gene, has helped infants achieve developmental milestones that are not possible with standard care [152, 153].”
Aronson, S. J., Bakker, R. S., Moenis, S., van Dijk, R., Bortolussi, G., Collaud, F., Shi, X., Duijst, S., ten Bloemendaal, L., Ronzitti, G., et al. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.06.002 · Cited by 29
Kerpel‐Fronius, S., Baroutsou, V., Becker, S., Carlesi, R. M., Collia, L., Franke-Bray, B., Kleist, P., Kurihara, C., Laranjeira, L. F., Matsuyama, K., et al. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.608249 · Cited by 29
Weber‐Adrian, D., Kofoed, R. H., Silburt, J., Noroozian, Z., Shah, K., Burgess, A., Rideout, S., Kügler, S., Hynynen, K., & Aubert, I. (2021) · Scientific Reports · doi:10.1038/s41598-021-81046-5 · Cited by 30
Pintacuda, G., Martín, J. M., & Eggan, K. C. (2021) · Molecular Autism · doi:10.1186/s13229-021-00417-x · Cited by 27
Feliciano, C. M., Wu, K., Watry, H. L., Marley, C. B. E., Ramadoss, G. N., Ghanim, H. Y., Liu, A. Z., Zholudeva, L. V., McDevitt, T. C., Saporta, M., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.723023 · Cited by 29
“Viral gene replacement therapy for the motor neuron disease spinal muscular atrophy (SMA) has shown great promise and could represent a viable strategy for the rare recessive forms of CMT2 (Mendell et al., 2017).”
BackgroundDual SMN inducing therapies can rescue survival and motor unit function in symptomatic ∆7SMA mice
Kray, K. M., McGovern, V. L., Chugh, D., Arnold, W. D., & Burghes, A. H. M. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105488 · Cited by 26
Self-citationChen, X., Niu, X., Liu, Y., Zheng, R., Yang, L., Lu, J., Yin, S., Wei, Y., Pan, J., Sayed, A. M. M., et al. (2022) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2022.06.001 · Cited by 25
Newborn screening for spinal muscular atrophy in Japan: One year of experience
Sawada, T., Kido, J., Sugawara, K., Yoshida, S., Ozasa, S., Nomura, K., Okada, K., Fujiyama, N., & Nakamura, K. (2022) · Molecular Genetics and Metabolism Reports · doi:10.1016/j.ymgmr.2022.100908 · Cited by 25
Motyl, A. A. L., & Gillingwater, T. H. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100725 · Cited by 25
“This study follows up the original trial for onasemnogene abeparvovec in 15 symptomatic SMA type I patients.(9) Following prenatal or newborn genetic confirmation of biallelic deletion of SMN1, 14 infants with two copies of SMN2 and 15 infants with three copies of SMN2 were treated at %6 weeks of life, before symptom…”
MethodUnique structural features govern the activity of a human mitochondrial AAA+ disaggregase, Skd3
Cupo, R. R., Rizo, A. N., Braun, G. A., Tse, E., Chuang, E., Gupta, K., Southworth, D. R., & Shorter, J. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111408 · Cited by 25
Ellsworth, J. L., Gingras, J., Smith, L. J., Rubin, H., Seabrook, T. A., Patel, K., Zapata, N., Olivieri, K., O’Callaghan, M., Chlipala, E., et al. (2019) · PLOS ONE · doi:10.1371/journal.pone.0225582 · Cited by 25
Alves, C. R. R., Zhang, R., Johnstone, A. J., Garner, R., Eichelberger, E. J., Lepez, S. D. S. D., Yi, V., Stevens, V., Poxson, R., Schwartz, R. L., et al. (2020) · Muscle & Nerve · doi:10.1002/mus.26995 · Cited by 25
Genetics and gene therapy in Dravet syndrome
Higurashi, N., Broccoli, V., & Hirose, S. (2021) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2021.108043 · Cited by 27
Vissers, M. F. J. M., Heuberger, J. A. A. C., & Groeneveld, G. J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041615 · Cited by 26
Embryo and fetal gene editing: Technical challenges and progress toward clinical applications
Mattar, C. N. Z., Chew, W. L., & Lai, P. S. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101229 · Cited by 26
Zaidman, C. M., Goedeker, N. L., Aqul, A. A., Butterfield, R. J., Connolly, A. M., Crystal, R. G., Godwin, K. E., Hor, K. N., Mathews, K. D., Proud, C. M., et al. (2024) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-230185 · Cited by 26
“Although studies conducted to evaluate other gene therapies (including onasemnogene abeparvovec and resamirigene bilparvovec) [10, 11] have identified similar AEs, this Delphi panel was focused specifically on discussing those TRAEs arising from delandistrogene moxeparvovec infusion.”
BackgroundSelf-citationNeurosurgical gene therapy for central nervous system diseases
Patel, R. V., Nanda, P., & Richardson, R. M. (2024) · Neurotherapeutics · doi:10.1016/j.neurot.2024.e00434 · Cited by 23
“An example is the development of the only in vivo viral vector therapeutic approved for a neurological disorder in the United States, onsasemnogene abeparvovec, an AAV9 based gene therapy for spinal muscular atrophy [13].”
BackgroundDisease Modeling and Therapeutic Strategies in CMT2A: State of the Art
Barbullushi, K., Abati, E., Rizzo, F., Bresolin, N., Comi, G. P., & Corti, S. P. (2019) · Molecular Neurobiology · doi:10.1007/s12035-019-1533-2 · Cited by 23
Neonatal hypotonia and neuromuscular conditions
Mercuri, E. M., Pera, M. C., & Brogna, C. (2019) · Handbook of clinical neurology · doi:10.1016/b978-0-444-64029-1.00021-7 · Cited by 32
Jiang, L., Lin, R., Gallagher, S., Zayac, A., Butchbach, M. E. R., & Hung, P. J. (2020) · Scientific Reports · doi:10.1038/s41598-020-76893-7 · Cited by 27
Systemic delivery of AAVrh74.tMCK.hCAPN3 rescues the phenotype in a mouse model for LGMD2A/R1
Sahenk, Z., Özeş, B., Murrey, D. A., Myers, M., Moss, K., YALVAÇ, M. E., Ridgley, A., Chen, L., & Mendell, J. R. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.06.010 · Cited by 25
Self-citationWang, Y.-C., Wu, Y., Choi, J. Y., Allington, G., Zhao, S., Khanfar, M., Yang, K., Fu, P.-Y., Wrubel, M., Yu, X., et al. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12020175 · Cited by 25
Liao, X.-H., Avalos, P., Shelest, O., Ofan, R., Shilo, M., Bresee, C. J., Likhite, S. B., Vit, J., Heuer, H., Kaspar, B. K., et al. (2022) · Thyroid · doi:10.1089/thy.2022.0034 · Cited by 25
“…were treated by a single intravenous (IV) infusion of adeno-associated virus serotype 9 (AAV9) containing DNA coding for SMN1, resulting in improved survival, as well as achievement of motor milestones and motor functions (22,23), with subsequent FDA approval of the gene therapy product Zolgensma.”
Self-citationNeonatal gene therapy achieves sustained disease rescue of maple syrup urine disease in mice
Pontoizeau, C., Sola, M. S., Gaborit, C., Nguyen, V., Rotaru, I., Tual, N., Colella, P., Girard, M., Biferi, M. G., Arnoux, J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30880-w · Cited by 26
Current AAV-mediated gene therapy in sensorineural hearing loss
Qi, J., Fu, X., Zhang, L., Tan, F., Li, N., Sun, Q., Hu, X., He, Z., Xia, M., & Chai, R. (2022) · Fundamental Research · doi:10.1016/j.fmre.2022.08.015 · Cited by 26
Onasemnogene Abeparvovec in Type 1 Spinal Muscular Atrophy: A Systematic Review and Meta-Analysis
Pascual‐Morena, C., Cavero‐Redondo, I., Lucerón‐Lucas‐Torres, M., Martínez‐García, I., Rodríguez‐Gutiérrez, E., & Martínez‐Vizcaíno, V. (2022) · Human Gene Therapy · doi:10.1089/hum.2022.161 · Cited by 24
“Seven studies included participants from the United States, 25,26,28,29,32,33,35 three from Europe, 27,28,34 two from Asia, 28,31 and one from Oceania.”
Kleynerman, A., Rybová, J., Faber, M. L., McKillop, W. M., Levade, T., & Medin, J. A. (2023) · Biomolecules · doi:10.3390/biom13020274 · Cited by 27
Kawabata, H., Konno, A., Matsuzaki, Y., & Hirai, H. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.02.016 · Cited by 24
“Comparison of the CNS tropism of BR1N with that of PHP.eB PHP.eB, an AAV9 capsid variant with a 7-amino-acid (TLAVPFK) insertion and flanking 2-amino-acid mutation at variable region VIII,13 was shown to cross the BBB with markedly higher efficacy than the parent AAV9.”
BackgroundInfluentialGardin, A., & Ronzitti, G. (2023) · Archives de Pédiatrie · doi:10.1016/s0929-693x(23)00227-0 · Cited by 25
Sprouty2—a Novel Therapeutic Target in the Nervous System?
Hausott, B., & Klimaschewski, L. P. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-1338-8 · Cited by 27
Suzuki‐Hatano, S., Saha, M., Soustek, M. S., Kang, P. B., Byrne, B. J., Cade, W. T., & Pacak, C. A. (2019) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2019.01.007 · Cited by 24
“As a multitude of AAV-mediated gene delivery strategies are currently being evaluated for clinical efficacy in humans to treat a range of genetically inherited disorders, a strong precedent exists, and our data support this as a strategy to be successfully translated into the clinic.(47,48)”
MethodPrenatal treatment path for angelman syndrome and other neurodevelopmental disorders
Zylka, M. J. (2019) · Autism Research · doi:10.1002/aur.2203 · Cited by 25
“Gene replacement therapies are used clinically to treat other single gene disorders, including spinalmuscular atrophy, a pediatric-onset neurological disorder [Mendell et al., 2017].”
BackgroundRescue of Advanced Pompe Disease in Mice with Hepatic Expression of Secretable Acid α-Glucosidase
Cagin, U., Puzzo, F., Gómez, M. J., Moya‐Nilges, M., Sellier, P., Abad, C., van Wittenberghe, L., Danièle, N., Guerchet, N., Gjata, B., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.05.025 · Cited by 27
Pandey, M., Ojha, D., Bansal, S., Rode, A. B., & Chawla, G. (2021) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2021.101003 · Cited by 23
Metadata
- Authors
- Mendell, J. R., Al-Zaidy, S., Shell, R., Arnold, W. D., Rodino-Klapac, L. R., Prior, T. W., Lowes, L., Alfano, L., Berry, K., Church, K., Kissel, J. T., Nagendran, S., L’Italien, J., Sproule, D. M., Wells, C., Cardenas, J. A., Heitzer, M. D., Kaspar, A., Corcoran, S., Braun, L., Likhite, S., Miranda, C., Meyer, K., Foust, K. D., Burghes, A. H. M., & Kaspar, B. K.
- Affiliations
- Abigail Wexner Research Institute (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-11-02
- Volume
- 377
- Issue
- 18
- Pages
- 1713-1722
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2765253110
- Cited by
- 2,381
- References
- 26
- Citations by year
- 2026: 205 · 2025: 232 · 2024: 292 · 2023: 270 · 2022: 289 · 2021: 347 · 2020: 298 · 2019: 246 · 2018: 172 · 2017: 16
- FWCI
- 115.14
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Nationwide Children's Hospital
- AveXis
- Research Institute, Nationwide Children's Hospital
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Keywords
- spinal muscular atrophy type 1, gene replacement therapy, adeno-associated virus vectors, SMN1, motor function, motor milestones, survival, CHOP INTEND, aminotransferase elevation, prednisolone, treatment efficacy and safety
- MeSH terms
- Dependovirus, Female, Genetic Vectors, Humans, Infant, Infant, Newborn, Infusions, Intravenous, Liver Diseases, Male, Motor Skills, Respiration, Artificial, Spinal Muscular Atrophies of Childhood, Genetic Therapy, Cohort Studies, Nutritional Support, Disease-Free Survival, Survival of Motor Neuron 1 Protein, Historically Controlled Study
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.